Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths in the world. More than half of patients with HCC present with advanced stage, and highly active systemic therapies are crucial for improving outcomes. Immune checkpoint inhibitor (ICI)-based therapies have emerg...

Descripción completa

Detalles Bibliográficos
Autores principales: Bicer, Fuat, Kure, Catrina, Ozluk, Anil A., El-Rayes, Bassel F., Akce, Mehmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670350/
https://www.ncbi.nlm.nih.gov/pubmed/37999131
http://dx.doi.org/10.3390/curroncol30110711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670350/
https://www.ncbi.nlm.nih.gov/pubmed/37999131
http://dx.doi.org/10.3390/curroncol30110711

Ejemplares similares